Specialty Pharmacy

Study estimates cancer will cause an economic burden of $8.3 trillion worldwide from 2011 to 2030.

A US Senate committee recently held a hearing to investigate the culprits behind the growing backlog of generic drug applications at the FDA.

A patient discusses her courageous battle with familial amyotrophic lateral sclerosis.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses how expensive hepatitis C drugs have impacted the specialty landscape.

Women diagnosed with malignant melanoma during pregnancy or within 1 year of giving birth were 5.1 times as likely to die.

Study indicates nearly 12,000 deaths related to the liver could be prevented from routine HCV screenings.

Improved colon cancer survival rate attributed to more aggressive treatment.

Dinutuximab is the first immunotherapy approved for the treatment of a pediatric cancer.

Afatinib showed significant improvement in progression-free survival and objective response rate in non-small cell lung cancer patients.

Nisin shows promise in killing cancer and deadly bacteria resistant to antibiotics.

Over the past 2 years, about 36 cases of acute hepatitis C virus infection were reported at 19 different hemodialysis clinics.

Annatto is commonly found in the seeds of the achiote fruit.

A former Walmart pharmacist was awarded around $31.2 million from her ex-employer after a federal jury decided that she was fired because of her gender and her concerns with understaffing and training.

Findings may lead to new treatment that protects nerves from damage caused in optic neuritis and throughout the central nervous system during MS attacks.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, discusses how specialty pharmacies can enhance their operations with data analytics.

Newly identified biomarker may help determine whether patients will need chemotherapy post-surgery.

Cutaneous psoriasis used to describe an individual who suffered from the disease for at least a decade.

Adcetris is currently the only approved molecular-targeted therapy for Hodgkins lymphoma.

Top news of the week in cancer drug development and research.

Serum antibody repertoires may serve as biomarkers for the pathology and progression of multiple sclerosis.

Study is the first to show a decrease in migraine frequency from medical marijuana.

Catch up with the latest developments across the health care landscape and sign up for key upcoming conferences and continuing education activities.

Catch up with the top news of the week from The American Journal of Pharmacy Benefits.

Top stories of the week on Specialty Pharmacy Times.

Zepatier is a once-daily, fixed-dose combination containing with the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir.

Halaven treats liposarcoma patients who received prior chemotherapy that contained an anthracycline drug.

Lynparza is a first in class PARP inhibitor for the monotherapy treatment of patients with metastatic castration resistant prostate cancer.

Venetoclax is an inhibitor of the B-cell lymphoma-2 protein used in combination with hypomethylating agents in treatment-naive AML patients.